

# A host-rotaxane derivatized with carboxylic acids efficiently delivers a highly cationic fluoresceinated peptide

Jing Zhu,<sup>a</sup> Brian E. House,<sup>a</sup> Erin Fleck,<sup>a</sup> Idit Isaacsohn,<sup>b</sup>  
Angela F. Drew<sup>b</sup> and David B. Smithrud<sup>a,\*</sup>

<sup>a</sup>Department of Chemistry, University of Cincinnati, Cincinnati, PO Box 210172, OH 45221, USA

<sup>b</sup>Department of Genome Science, University of Cincinnati, Cincinnati, OH 45237, USA


Received 18 May 2007; revised 5 July 2007; accepted 6 July 2007

Available online 13 July 2007

**Abstract**—A cleft-[2]rotaxane (CR2+2–) was derivatized with carboxylic acids to enhance the intracellular delivery of a highly cationic or anionic pentapeptide. CR2+2– delivers the fluorescein (Fl) tagged peptide Fl-KKALR to a greater amount than Fl-QEAVD, and at a higher concentration, a greater amount than Fl-AVWAL. The level of delivery is largely temperature and ATP independent, suggesting that the Fl-peptide-CR2+2– complexes pass through the cellular membrane without requiring active cell-mediated processes. This study shows that selective delivery of peptides is possible by using a suitably derivatized host-rotaxane as the transporter.

© 2007 Elsevier Ltd. All rights reserved.

Peptides hold great promise as therapeutic agents. Their potential, however, is severely limited by the inability of most peptides to passively pass through cellular membranes because of their amide bonds and the existence of any polar or charged side chains. Although several methods have been developed recently to deliver materials into cells, most rely on endocytosis for membrane passage, and thus the delivered material needs to be covalently or noncovalently prepackaged often resulting in highly cationic devices which can result in high toxicity.<sup>1–8</sup> Herein we show for the first time that a host-rotaxane can be derivatized with carboxylic acids (CR2+2–, Fig. 1), which gives it an overall small charge of 1+ in buffered water (pH 7.3), and still be an efficient intracellular delivery agent that operates independently of cellular energy. CR2+2– can deliver a greater amount of a highly cationic, fluoresceinated (Fl) pentapeptide (Fl-KKALR) into cells than a Fl-peptide containing apolar (Fl-AVWAL) or negatively charged side chains (Fl-QEAVD). Apparently, interactions between the carboxylates of CR2+2– and the cationic side chains of Fl-KKALR promote membrane passage. These findings show that the selective delivery of small



**Figure 1.** Cleft-[2]rotaxane CR2+2– delivers the Fl-peptides into cells.

peptides of all charges is possible by using a suitably derivatized host-rotaxane as the transporter.

Rotaxanes are compounds with an interlocked wheel and axle with blocking groups on the ends of the axle (Fig. 1).<sup>9</sup> We converted them into host-rotaxanes (HRs) by using a synthetic host as one of the blocking groups.<sup>10</sup> Using fluorescein-labeling, we recently showed that a HR delivers Fl-pentapeptides into cells.<sup>11</sup> A comparison of cellular fluorescence showed that, not surpris-

**Keywords:** Transporters; Rotaxanes; Host-guest chemistry; Peptide mimics.


\* Corresponding author. E-mail: [david.smithrud@uc.edu](mailto:david.smithrud@uc.edu)

ingly, FI-AVWAL, which contains apolar side chains, is delivered into cells with 1.5 times greater efficiency than FI-KKALR and 2.2 times more efficiently than FI-QEAVD. To be effective delivery devices, transporters also need to selectively deliver targeted peptides that contain charged side chains. The goal of this research program was to design a transporter that would selectively deliver a highly charged peptide over an uncharged peptide. This is not trivial considering that apolar compounds generally form more stable complexes in water and are more lipophilic than charged compounds. We predicted that adding functional groups to the transporter that are complementary to the charged side chains would result in a greater amount of that peptide being delivered.

CR2+2<sup>−</sup> was derivatized with carboxylic acids and guanidines (Supporting Information) to promote association with FI-KKALR or FI-QEAVD, respectively, through salt-bridge formation. FI-AVWAL was also used as a guest. The peptides were presented as carboxamides (FI-peptideCONH<sub>2</sub>). Intramolecular interactions are possible between the guanidinium and carboxylate ions of CR2+2<sup>−</sup>, which could weaken intermolecular interactions in the FI-peptide-CR2+2<sup>−</sup> complexes. The arginines were utilized because of their likely importance in cellular transport.<sup>6</sup> Selective complex formation should lead to selective delivery if transport occurs through a cell-passive mechanism. Large differences in stability may be needed if the permeability of the complex controls the level of transport. In this case, the delivery efficiencies would be FI-AVWAL > FI-KKALR > FI-QEAVD since the overall charge of the FI-peptide-CR2+2<sup>−</sup> complexes, in water at pH 7.3, would be 1<sup>−</sup>, 2<sup>+</sup>, and 3<sup>−</sup>, respectively. The overall charge is based on the fluorescein moiety of the FI-peptide existing as a dianion.<sup>12</sup>

The ability of the CR2+2<sup>−</sup> to deliver the FI-peptides was initially screened using fluorescence microscopy. Figure 2 shows that high and moderate fluorescence is observed in cells exposed to CR2+2<sup>−</sup> (20 μM) and FI-AVWAL (10 μM) or FI-KKALR (10 μM). Cells exposed to CR2+2<sup>−</sup> (20 μM) and FI-QEAVD (10 μM), however, were only weakly fluorescent, similar to the background fluorescence obtained from exposure to the FI-peptides (10 μM) alone. Calcein blue AM (cbAM, Invitrogen) and propidium iodide (PI) were added to confirm low toxicity and high viability of cells exposed to CR2+2<sup>−</sup> and peptides.

Flow cytometry was used to quantify the relative levels of FI-AVWAL, FI-KKALR, FI-QEAVD, cbAM, and PI within the cells. The threshold for background fluorescence was set using cells incubated with a FI-peptide (10 μM) alone, as previously described.<sup>13</sup> Generally, increasing the concentration of CR2+2<sup>−</sup> results in a greater amount of FI-peptide delivered (Table 1 and Fig. 3), which is consistent with a noncovalent complex forming between the transporter and a FI-peptide during the delivery process. The delivery level of FI-KKALR appears to peak at a concentration of 40 μM. The amount of FI-QEAVD delivered slowly rises and



**Figure 2.** Fluorescence microscopy of COS 7 cells incubated with CR2+2<sup>−</sup> (20 μM) and (A) FI-AVWAL (10 μM), (B) FI-KKALR (10 μM), and (C) FI-QEAVD (10 μM). FI-peptide (peptide uptake; left panels), white light (middle panels), and calcein blue AM fluorescence (viability; right panels). Original magnification: 100×.


appears to maximize at 25% of cells being penetrated. Thus, CR2+2<sup>−</sup> more efficiently transports FI-KKALR than FI-QEAVD at the concentrations used in the assays. FI-AVWAL and FI-KKALR are delivered in increasing amounts until a concentration of 40 μM is reached. At this concentration of CR2+2<sup>−</sup>, a dramatic reduction in the delivery of FI-AVWAL is seen.

We have previously observed lower than expected percentage of fluorescent cells after FI-AVWAL (10 μM) delivery in an assay performed at 4 °C.<sup>14</sup> FI-AVWAL or its complex with an HR appeared to precipitate on the surface of the cells in that assay, which may be caused by poor solubility. The FI-AVWAL-CR2+2<sup>−</sup> complex has a single charge in the buffered solution and the peptidic residues are apolar. Increasing the concentration FI-AVWAL will result in a greater concentration of the FI-AVWAL-CR2+2<sup>−</sup> complex, which could precipitate at a high concentration. Thus, CR2+2<sup>−</sup> more efficiently delivers FI-KKALR than FI-AVWAL at the higher concentrations of the components.

A high proportion of calcein blue positive cells (80–98%) was observed in the assays, demonstrating that the CRs and FI-peptides are minimally or not toxic at these concentrations. Less than 3% of the cells were dead, according to the level of PI observed within the cells. Calcein

**Table 1.** Quantification of FI-peptide uptake in COS 7 cells by flow cytometry<sup>a</sup>

Condition	Peptide <sup>b</sup>	[CR2+2-] ( $\mu$ M)	%FI-peptide	%cbAM <sup>c</sup>
rt	FI-AVWAL	40	25	95
	FI-AVWAL	20	73	86
	FI-AVWAL	10	54	84
	FI-AVWAL	5	31	82
	FI-AVWAL	0	5	86
	FI-KKALR	40	84	82
	FI-KKALR	20	61	84
	FI-KKALR	10	43	88
	FI-KKALR	5	30	98
	FI-KKALR	0	5	92
	FI-QEAVD	40	23	80
	FI-QEAVD	20	18	92
	FI-QEAVD	10	12	81
	FI-QEAVD	5	8	90
	FI-QEAVD	0	5	89
Depleted ATP <sup>d</sup>	FI-AVWAL	10	53	81
	FI-KKALR	20	65	93
4 °C	FI-AVWAL	10	30	83
	FI-KKALR	20	55	85

<sup>a</sup> All transport assays were performed in PBS (pH 7.3) for 1 h.<sup>b</sup> [FI-peptide] = 10  $\mu$ M.<sup>c</sup> [Calcein blue AM] = 1  $\mu$ M.<sup>d</sup> The assay solutions contained 2-deoxyglucose and NaN<sub>3</sub>.**Figure 3.** Saturation of fluorescence intensity is observed as the concentration of CR2+2- is raised. CR2+2- and FI-AVWAL (10  $\mu$ M) (triangles), FI-KKALR (10  $\mu$ M) (squares), or FI-QEAVD (10  $\mu$ M) (circles) at room temperature (green), with depleted ATP (red), and at 4 °C (blue). The FI-peptide line (x's) represents all the peptides used in this assay, and it was set at a 5% level.<sup>11</sup> The lines show the trends in the plots.


blue/propidium iodide and FI-peptide fluorescence were independent variables. Membrane integrity was also verified by measuring the amount of enzyme released from the cells during the assay. The level of lactate dehydrogenase (LDH, CytoTox-One Integrity Assay, Promega) released into the solution was 7–9% for untreated cells and cells exposed to the various reagents.

In our design of selective delivery agents, we assumed that the transport process occurs through a cell-passive

mechanism that requires the complexes to pass through the membrane. Some highly argininated peptides, however, enter cells through endocytosis.<sup>15</sup> To determine whether endocytosis is the major pathway for cellular entry, the assays were repeated at 4 °C or by using an established ATP-depleting cocktail of 2-deoxyglucose and NaN<sub>3</sub> to deplete the cellular energy.<sup>15</sup> A similar level of transport was observed for the FI-peptides under the energy-depleted conditions, except for the 44% reduction in the transport level of FI-AVWAL at 4 °C. As discussed above, we have previously observed a reduction in FI-AVWAL delivery at 4 °C, and this is likely due to a decreased solubility rather than the involvement of endocytosis.

To verify that depleting the energy of the cells does not alter the transport mechanism, the location and intensity of the intracellularly delivered FI-peptides were observed under 400 $\times$  magnification. COS 7 cells were grown on microscope slides. After exposing the cells to the various reagents, the unfixed cells were examined by fluorescence microscopy. Cells exposed to FI-KKALR showed sharply defined cellular compartments (Fig. 4A–C). FI-AVWAL was localized more uniformly throughout the cell (Fig. 4D–F). The distribution and the fluorescence intensity of the FI-peptides do not change for cells lacking energy-dependent pathways. These observations combined with the flow cytometric results show that endocytosis is not the major pathway for the delivery of materials into cells. A cell-passive, rotaxane-dependent mechanism is more likely followed.

The low percentage of cells containing PI, the high percentage of cells with cbAM, and the low amount of LDH released into the assay solutions indicate membrane leakage does not account for transport efficiency. Furthermore if CR2+2- caused membrane leakage, increasing its concentration should increase the percentage of fluorescent cells until cell death occurs. Pore formation is not consistent with the data shown in Figure 3. The observed concentration dependency can be explained by a complex being formed between CR2+2- and a FI-peptide during the delivery process.


**Figure 4.** Fluorescence photomicrographs showing representative examples of COS 7 cells exposed to CR2+2- (20  $\mu$ M) and FI-KKALR (10  $\mu$ M) (A–C) and FI-AVWAL (10  $\mu$ M) (D–F) at rt (A and D), 4 °C (B and E), and depleted ATP (C and F). Original magnification: 400 $\times$ .

**Table 2.** Association constants ( $M^{-1}$ ) for CR2+2 $^{-}$  complexes<sup>a</sup>

Solvent	FI-AVWAL	FI-KKALR	FI-QEAVD
Water <sup>b</sup>	$2.7 \times 10^4$	$3.0 \times 10^3$	$5.0 \times 10^3$
DMSO	$1.5 \times 10^5$	$9.0 \times 10^4$	$4.9 \times 10^4$

<sup>a</sup> The assays were performed at room temperature, the standard deviation is less than 10% for each  $K_A$ .

<sup>b</sup> 98% water (PBS 1 mM, pH 7.3)/2% DMSO.



**Figure 5.** Concentration dependency for transport levels FI-KKALR (squares), FI-AVWAL (triangles, [CR2+2 $^{-}$ ] 40  $\mu M$  is excluded), and FI-QEAVD ( $\times$ 's). Blue indicates the concentration of a complex in water and red DMSO. Standard deviation for both data sets is less than 10%.

Differences in the delivery levels of peptides can arise from the superior solubility (aqueous phase or membrane) or stability of its CR2+2 $^{-}$ -FI-peptide complex as compared to other complexes.

We determined the association constants ( $K_A$ 's, Supporting Information) for the FI-peptide-CR2+2 $^{-}$  complexes in water (PBS, pH 7.3) and DMSO. These solutions are used to represent the extracellular domain and interface of cells, which is the region of the phosphate head groups, respectively. As expected, the most stable complex in water occurs for the binding of the most apolar peptide FI-AVWAL (Table 2). The FI-KKALR-CR2+2 $^{-}$  and FI-QEAVD-CR2+2 $^{-}$  complexes are weaker and have similarly sized  $K_A$ 's. Interaction with the side chains of these peptides requires the removal of water molecules, resulting in a large desolvation penalty for complexation. The same trend in stability for guest binding is observed in DMSO. The magnitude of  $K_A$ 's, however, is significantly larger in DMSO than water, which is consistent with a diminished desolvation penalty.

Using the  $K_A$ 's derived in water and DMSO, the concentration of the various FI-peptide-CR2+2 $^{-}$  complexes can be derived. Linear correlations exist between the concentrations of a FI-peptide-CR2+2 $^{-}$  complex versus the percentage of cells that contain that FI-peptide, excluding the data point for cells exposed to 40  $\mu M$  CR2+2 $^{-}$  and FI-AVWAL (Fig. 5). The slopes of the

lines for a complex are greater in water than DMSO. If the amount of a complex in water dictates the amount of FI-peptide that enters the cells, FI-KKALR is delivered more efficiently than FI-AVWAL. If complex strength in a DMSO environment is a better indicator of transport, then FI-KKALR and FI-AVWAL are delivered in a similar amount. In either case, the FI-QEAVD-CR2+2 $^{-}$  complex has the lowest permeability. The ability of CR2+2 $^{-}$  to deliver FI-KKALR as well as or better than FI-AVWAL is remarkable considering that FI-AVWAL has apolar side chains and the overall charge of its complex with CR2+2 $^{-}$  is one less than the FI-KKALR-CR2+2 $^{-}$  complex in water (pH 7.3).

Here we show that a cleft-[2]rotaxane derivatized with carboxylic acids and guanidines on the wheel can more efficiently deliver a highly cationic peptide over peptides containing negative charges or apolar side chains. In the presence of a high concentration of CR2+2 $^{-}$ , the percentage of fluorescent cells was approximately four times greater for cells exposed to FI-KKALR than to FI-QEAVD or FI-AVWAL. We are currently designing transporters that will selectively deliver other peptides with various side chains into cells with the long-term goal of efficiently delivering therapeutic peptides into targeted cells.

## Acknowledgments

The work was supported by the National Science Foundation under Grant No. CHE-0400539 and the American Cancer Society, Ohio Division, Inc., (AFD).

## Supplementary data

Supplementary Information: includes the synthesis of CR2+2 $^{-}$  and the methods used to determine  $K_A$ 's. Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.bmcl.2007.07.013](https://doi.org/10.1016/j.bmcl.2007.07.013).

## References and notes

- Li, W. J.; Szoka, F. C. *Pharm. Res.* **2007**, *24*, 438.
- Yamagata, M.; Kawano, T.; Shiba, K.; Mori, T.; Katayama, Y.; Niidome, T. *Bioorg. Med. Chem.* **2007**, *15*, 526.
- Rao, N. M.; Gopal, V. *Biosci. Rep.* **2006**, *26*, 301.
- Jones, L. R.; Goun, E. A.; Shinde, R.; Rothbard, J. B.; Contag, C. H.; Wender, P. A. *J. Am. Chem. Soc.* **2006**, *128*, 6526.
- Mae, M.; Langel, U. *Curr. Opin. Pharmacol.* **2006**, *6*, 509.
- (a) Futaki, S. *Biopolymers* **2006**, *84*, 241; (b) Futaki, S. *Adv. Drug Delivery Rev.* **2005**, *57*, 547.
- Kawakami, H.; Toma, K.; Hattori, Y.; Maitani, Y. *Bioconjugate Chem.* **2006**, *17*, 935.
- Chen, H. T.; Neerman, M. F.; Parrish, A. R.; Simanek, E. E. *J. Am. Chem. Soc.* **2004**, *126*, 10044.
- Molecular Catenanes, Rotaxanes and Knots: A Journey Through the World of Molecular Topology*; Sauvage, J.-P., Dietrich-Buchecker, C. O., Eds.; Wiley-VCH: Weinheim, 1999.

10. Smukste, I.; House, B. E.; Smithrud, D. B. *J. Org. Chem.* **2003**, 68, 2559.
11. Wang, X.; Bao, X.; McFarland-Mancini, M.; Isaacsohn, I.; Drew, A. F.; Smithrud, D. B. *J. Am. Chem.* **2007**, 129, 7284.
12. Król, M.; Wrona, M.; Page, C. S.; Bates, P. A. *J. Chem. Theory Comput.* **2006**, 2, 1520.
13. Bao, X.; Isaacsohn, I.; Drew, A. F.; Smithrud, D. B. *J. Am. Chem. Soc.* **2006**, 128, 12229.
14. Bao, X.; Isaacsohn, I.; Drew, A. F.; Smithrud, D. B. *J. Org. Chem.* **2007**, 72, 3988.
15. Richard, J. P.; Melikov, K.; Vives, E.; Ramos, C.; Verbeure, B.; Gait, M. J.; Chernomordik, L. V.; Lebleu, B. *J. Biol. Chem.* **2003**, 278, 585.